Aurora Cannabis Inc.

ACB · NASDAQ

Aurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal-control weaknesses, and an open ATM keep the turnaround on probation.

Follow Add to Watchlist Ask Question

NASDAQ ACB Coverage Bootstrap Cannabis Medical Cannabis Turnaround

Latest ReportMay 13, 2026Aurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.